Biotech News
-
Zentek to Present at the Sidoti & Company Virtual Small Cap Conference
January 17, 2022 (Source) — Zentek Ltd. (“ZEN” or the “Company”) (TSX-V:ZEN) and (OTC:ZENYF), an IP development and commercialization…
-
Zentek Announces Grant of Stock Options
January 14, 2022 (Source) — Zentek Ltd. (“ZEN” or the “Company”) (TSXV:ZEN)(OTC PINK:ZENYF), an IP development and commercialization company…
-
Awakn Responds to OTC Markets Request on Recent Promotional Activity
January 14, 2022 (Source) — Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) (FSE: 954) (“Awakn”), a biotechnology company…
-
Zentek Announces Binding Letter of Intent with GMAF Circular Medico for ZENGuard(TM)-Enhanced Circular PPE(TM)
January 13, 2022 (Source) — Zentek Ltd. (“ZEN” or the “Company”) (TSXV:ZEN)(OTC PINK:ZENYF), a Canadian IP development and commercialization…
-
XPhyto signs Distribution Agreement for Czech Republic, rollout planned for Hungary, Slovakia, Ukraine and Russia
January 13, 2022 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY)(OTC:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce that it…
-
Voyageur Pharmaceuticals Announces IRR of 137% and NPV of $344 Million from Preliminary Economic Assessment for the Frances Creek Pharmaceutical Barium Project
January 11, 2022 (Source) — Voyageur Pharmaceuticals Ltd. (“Voyageur” or the “Company”) (TSXV: VM) is pleased to announce…
-
Hemostemix to Combine ACP-01 with Dr. James Shapiro’s Islet Cells to Treat Type 1 Diabetes
January 11, 2022 (Source) — Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF) (FSE: 2VFO) (“Hemostemix” or the “Company”) is pleased…
-
Awakn Life Sciences Announces Positive Results from Phase II A/B Ketamine-Assisted Therapy for Treatment of Alcohol Use Disorder Trial
Primary and Secondary Endpoints Achieved, Including 86% Abstinence Over 6 Months Post Treatment and No Serious Adverse Events…
-
Zentek Announces First Direct Orders Under Its Medical Device Establishment License
January 11, 2022 (Source) — Zentek Ltd. (“ZEN” or the “Company”) (TSX-V:ZEN and OTC:ZENYF), a Canadian IP development and commercialization…
-
XPhyto Announces New Director of Business Development and Head of Diagnostic Research
January 10, 2022 (Source) — XPhyto Therapeutics Corp. (CSE:XPHY)(OTCQB:XPHYF)(FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce two key appointments…
